PRESS RELEASE

Q4 2023 — Press release

Q4 2023PDF · 20 pages377 KB
News Release
Abbott Reports Fourth-Quarter and Full-Year 2023 Results;
Issues 2024 Financial Outlook
– Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the
underlying base business increased 11.0 percent
– Full-year 2023 reported sales decreased 8.1 percent due to anticipated decline in
COVID-19 testing-related sales; organic sales growth for the underlying base business
increased 11.6 percent
– Full-year 2023 GAAP diluted EPS of $3.26; adjusted diluted EPS of $4.44
– R&D pipeline continues to deliver steady cadence of new products
ABBOTT PARK, Ill., Jan. 24, 2024 — Abbott today announced financial results for the fourth quarter
ended Dec. 31, 2023.
• Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and
11.0 percent on an organic basis, excluding COVID-19 testing-related sales1.
• Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19, which excludes
specified items.
• Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-
year adjusted diluted EPS of $4.50 to $4.70.
• Abbott projects full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be
in the range of 8.0% to 10.0%2.
• In 2023, Abbott continued to recapture market share in the U.S. infant formula market. The
company has now reclaimed its previous market-leading position, as measured on a volume basis.
• In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its new
laboratory automation system, GLP systems Track™, to help laboratories optimize performance and
safety to better meet the growing demand for diagnostic testing.
• In January, Abbott announced that the first-in-human procedures were conducted using the
company's new Volt™ Pulsed Field Ablation (PFA) System to treat patients with heart rhythm
disorders such as atrial fibrillation (AFib). These procedures were part of Abbott's Volt CE Mark
clinical study. Abbott anticipates approval for its U.S. clinical trial (IDE) for the Volt PFA System in
the first half of 2024.
• In January, Abbott announced that Tandem Diabetes Care's t:slim X2™3 insulin pump is the first
automated insulin delivery system in the U.S. to integrate with Abbott's new FreeStyle Libre® 2 Plus
sensor.
"The strength and diversity of the Abbott portfolio drove our success in 2023," said Robert B. Ford,
chairman and chief executive officer, Abbott. "We're entering 2024 with a lot of positive momentum, and
with our highly productive pipeline, we're well-positioned for growth in 2024 and beyond."
-- more --
Page 1 of 20

-- 1 of 20 --

FOURTH-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign
exchange, the impact of exiting the pediatric nutrition business in China, and the impact of the acquisition of
Cardiovascular Systems, Inc. (CSI), is an appropriate way for investors to best understand the core underlying
performance of the business. Management further believes that measuring sales growth rates on an organic basis
excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as
the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or
divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or
divided, as appropriate, by the prior year average foreign exchange rates.
Fourth Quarter 2023 Results (4Q23)
Sales 4Q23 ($ in millions) Total Company Nutrition Diagnostics Established
Pharmaceuticals Medical Devices
U.S. 3,949 860 1,020 — 2,065
International 6,292 1,178 1,514 1,222 2,378
Total reported 10,241 2,038 2,534 1,222 4,443
% Change vs. 4Q22
U.S. (6.4) 8.2 (38.8) n/a 17.6
International 7.2 15.3 (6.0) 0.5 17.5
Total reported 1.5 12.2 (22.7) 0.5 17.5
Impact of foreign exchange (0.8) (0.7) (0.4) (8.3) 1.0
Impact of CSI acquisition 0.4 — — — 1.1
Impact of business exit (0.2) (1.0) — — —
Organic 2.1 13.9 (22.3) 8.8 15.4
Impact of COVID-19 testing sales (4) (8.9) — (24.5) — —
Organic (excluding COVID-19 tests) 11.0 13.9 2.2 8.8 15.4
U.S. 7.1 8.2 (10.7) n/a 15.5
International 13.4 18.5 10.9 8.8 15.4
Full-Year 2023 Results (12M23)
Sales 12M23 ($ in millions) Total Company Nutrition Diagnostics Established
Pharmaceuticals Medical Devices
U.S. 15,452 3,413 4,329 — 7,696
International 24,657 4,741 5,659 5,066 9,191
Total reported 40,109 8,154 9,988 5,066 16,887
% Change vs. 12M22
U.S. (14.8) 16.9 (49.3) n/a 15.2
International (3.3) 4.4 (28.7) 3.1 13.2
Total reported (8.1) 9.3 (39.4) 3.1 14.1
Impact of foreign exchange (2.0) (2.3) (1.2) (7.8) (1.0)
Impact of CSI acquisition 0.3 — — — 0.9
Impact of business exit (0.2) (1.4) — — —
Organic (6.2) 13.0 (38.2) 10.9 14.2
Impact of COVID-19 testing sales (4) (17.8) — (44.0) — —
Organic (excluding COVID-19 tests) 11.6 13.0 5.8 10.9 14.2
U.S. 11.3 16.9 1.3 n/a 13.3
International 11.7 10.4 8.5 10.9 14.9
Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.
-- more --
Page 2 of 20

-- 2 of 20 --

Nutrition
Fourth Quarter 2023 Results (4Q23)
Sales 4Q23 ($ in millions) Total Pediatric Adult
U.S. 860 505 355
International 1,178 480 698
Total reported 2,038 985 1,053
% Change vs. 4Q22
U.S. 8.2 11.4 4.0
International 15.3 12.3 17.4
Total reported 12.2 11.8 12.5
Impact of foreign exchange (0.7) (0.5) (0.9)
Impact of business exit (1.0) (2.2) —
Organic 13.9 14.5 13.4
U.S. 8.2 11.4 4.0
International 18.5 17.9 18.9
Worldwide Nutrition sales increased 12.2 percent on a reported basis and 13.9 percent on an organic basis in the
fourth quarter. Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.
In Pediatric Nutrition, global sales increased 11.8 percent on a reported basis and 14.5 percent on an organic
basis. International sales increased 12.3 percent on a reported basis and 17.9 percent on an organic basis, which
was led by strong growth in Canada and several countries in Latin America. In the U.S., sales growth of 11.4
percent was primarily driven by market share recovery in the infant formula business following a voluntary
recall of certain products last year.
In Adult Nutrition, global sales increased 12.5 percent on a reported basis and 13.4 percent on an organic basis,
which was led by strong global growth of Ensure®, Abbott's market-leading complete and balanced nutrition
brand.
Full-Year 2023 Results (12M23)
Sales 12M23 ($ in millions) Total Pediatric Adult
U.S. 3,413 1,977 1,436
International 4,741 1,957 2,784
Total reported 8,154 3,934 4,220
% Change vs. 12M22
U.S. 16.9 26.6 5.8
International 4.4 2.0 6.2
Total reported 9.3 13.0 6.1
Impact of foreign exchange (2.3) (1.8) (2.7)
Impact of business exit (1.4) (3.1) —
Organic 13.0 17.9 8.8
U.S. 16.9 26.6 5.8
International 10.4 10.3 10.4
-- more --
Page 3 of 20

-- 3 of 20 --

Diagnostics
Fourth Quarter 2023 Results (4Q23)
Sales 4Q23 ($ in millions) Total Core Laboratory Molecular Point of Care Rapid
Diagnostics *
U.S. 1,020 326 44 107 543
International 1,514 1,044 109 42 319
Total reported 2,534 1,370 153 149 862
% Change vs. 4Q22
U.S. (38.8) 8.3 (27.7) 20.7 (55.3)
International (6.0) 8.4 (7.8) (1.0) (34.4)
Total reported (22.7) 8.4 (14.6) 13.6 (49.3)
Impact of foreign exchange (0.4) (0.7) 0.3 0.6 (0.1)
Organic (22.3) 9.1 (14.9) 13.0 (49.2)
Impact of COVID-19 testing sales (4) (24.5) (0.6) (16.6) — (35.5)
Organic (excluding COVID-19 tests) 2.2 9.7 1.7 13.0 (13.7)
U.S. (10.7) 8.8 (12.6) 20.7 (29.2)
International 10.9 10.0 8.2 (2.9) 18.6
As expected, Diagnostics sales growth in the fourth quarter was negatively impacted by year-over-year declines
in COVID-19 testing-related sales4. Worldwide COVID-19 testing sales were $288 million in the fourth quarter
of 2023 compared to $1.069 billion in the fourth quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 1.7 percent on a reported basis and
2.2 percent on an organic basis.
Full-Year 2023 Results (12M23)
Sales 12M23 ($ in millions) Total Core Laboratory Molecular Point of Care Rapid
Diagnostics *
U.S. 4,329 1,243 172 396 2,518
International 5,659 3,916 402 169 1,172
Total reported 9,988 5,159 574 565 3,690
% Change vs. 12M22
U.S. (49.3) 9.3 (53.6) 6.4 (62.1)
International (28.7) 4.4 (35.7) 10.3 (65.6)
Total reported (39.4) 5.5 (42.3) 7.5 (63.3)
Impact of foreign exchange (1.2) (2.9) (0.7) (0.2) (0.4)
Organic (38.2) 8.4 (41.6) 7.7 (62.9)
Impact of COVID-19 testing sales (4) (44.0) (1.0) (33.5) — (64.2)
Organic (excluding COVID-19 tests) 5.8 9.4 (8.1) 7.7 1.3
U.S. 1.3 10.1 (17.8) 6.4 (4.8)
International 8.5 9.1 (3.8) 10.8 11.6
*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result,
$28 million of sales in the fourth quarter of 2022 and $115 million in the full-year 2022 were moved from Rapid Diagnostics to Heart
Failure.
-- more --
Page 4 of 20

-- 4 of 20 --

Established Pharmaceuticals
Fourth Quarter 2023 Results (4Q23)
Sales 4Q23 ($ in millions) Total Key Emerging
Markets Other
U.S. — — —
International 1,222 918 304
Total reported 1,222 918 304
% Change vs. 4Q22
U.S. n/a n/a n/a
International 0.5 0.5 0.4
Total reported 0.5 0.5 0.4
Impact of foreign exchange (8.3) (10.9) (0.4)
Organic 8.8 11.4 0.8
U.S. n/a n/a n/a
International 8.8 11.4 0.8
Established Pharmaceuticals sales increased 0.5 percent on a reported basis and 8.8 percent on an organic basis
in the fourth quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth
opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.5 percent
on a reported basis and increased 11.4 percent on an organic basis, led by growth in several geographies and
therapeutic areas, including cardiometabolic, gastroenterology, respiratory, and central nervous system/pain
management.
Full-Year 2023 Results (12M23)
Sales 12M23 ($ in millions) Total Key Emerging
Markets Other
U.S. — — —
International 5,066 3,807 1,259
Total reported 5,066 3,807 1,259
% Change vs. 12M22
U.S. n/a n/a n/a
International 3.1 1.1 9.8
Total reported 3.1 1.1 9.8
Impact of foreign exchange (7.8) (9.2) (3.0)
Organic 10.9 10.3 12.8
U.S. n/a n/a n/a
International 10.9 10.3 12.8
-- more --
Page 5 of 20

-- 5 of 20 --

Medical Devices
Fourth Quarter 2023 Results (4Q23)
Sales 4Q23 ($ in millions) Total Rhythm
Management Electro-
physiology Heart
Failure * Vascular Structural
Heart Neuro-
modulation Diabetes
Care
U.S. 2,065 285 279 227 245 231 197 601
International 2,378 297 314 74 432 267 43 951
Total reported 4,443 582 593 301 677 498 240 1,552
% Change vs. 4Q22
U.S. 17.6 12.0 15.0 13.6 14.8 7.9 20.8 28.3
International 17.5 14.5 28.0 26.6 10.4 17.6 10.2 18.4
Total reported 17.5 13.3 21.5 16.6 12.0 12.9 18.8 22.0
Impact of foreign exchange 1.0 1.2 0.3 1.2 1.1 1.5 — 1.3
Impact of CSI acquisition 1.1 — — — 6.4 — — —
Organic 15.4 12.1 21.2 15.4 4.5 11.4 18.8 20.7
U.S. 15.5 12.0 15.0 13.6 (2.5) 7.9 20.8 28.3
International 15.4 12.1 27.3 21.4 8.3 14.7 10.2 16.2
Worldwide Medical Devices sales increased 17.5 percent on a reported basis and 15.4 percent on an organic basis
in the fourth quarter. Sales growth was led by double-digit organic growth in Diabetes Care, Neuromodulation,
Structural Heart, Electrophysiology, Heart Failure, and Rhythm Management. Several recently launched
products and new indications contributed to the strong performance, including Amplatzer®, Amulet®, Navitor®,
TriClip®, and AVEIR®.
In Electrophysiology, internationally, sales grew more than 25.0 percent on a reported and organic basis, which
included sales growth of more than 20.0 percent in Europe.
In Diabetes Care, FreeStyle Libre sales were $1.4 billion, which represents sales growth of 25.5 percent on a
reported basis and 23.8 percent on an organic basis.
Full-Year 2023 Results (12M23)
Sales 12M23 ($ in millions) Total Rhythm
Management Electro-
physiology Heart
Failure * Vascular Structural
Heart Neuro-
modulation Diabetes
Care
U.S. 7,696 1,085 1,008 888 978 883 725 2,129
International 9,191 1,170 1,187 273 1,703 1,061 165 3,632
Total reported 16,887 2,255 2,195 1,161 2,681 1,944 890 5,761
% Change vs. 12M22
U.S. 15.2 5.5 10.8 9.6 13.2 7.9 17.2 30.3
International 13.2 7.4 16.6 21.1 5.2 18.7 9.0 16.3
Total reported 14.1 6.5 13.9 12.1 8.0 13.6 15.5 21.1
Impact of foreign exchange (1.0) (1.0) (2.0) 0.1 (1.3) (0.7) (0.9) (0.8)
Impact of CSI acquisition 0.9 — — — 5.3 — — —
Organic 14.2 7.5 15.9 12.0 4.0 14.3 16.4 21.9
U.S. 13.3 5.5 10.8 9.6 (1.0) 7.9 17.2 30.3
International 14.9 9.4 20.5 20.5 6.7 20.1 13.1 17.5
*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result,
$28 million of sales in the fourth quarter of 2022 and $115 million in the full-year 2022 were moved from Rapid Diagnostics to Heart
Failure.
-- more --
Page 6 of 20

-- 6 of 20 --

ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.20 to $3.40. Abbott
forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible
amortization, costs associated with acquisitions, restructuring and cost reduction initiatives and other
net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.50
to $4.70 for the full-year 2024.
ABBOTT DECLARES 400TH CONSECUTIVE QUARTERLY DIVIDEND
On Dec. 15, 2023, the board of directors of Abbott declared the company's quarterly dividend of $0.55
per share. Abbott's cash dividend is payable Feb. 15, 2024, to shareholders of record at the close of
business on Jan. 12, 2024.
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500
Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at
least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
of life-changing technologies spans the spectrum of healthcare, with leading businesses and products
in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on
Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations
website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast
will be available later in the day.
-- more --
Page 7 of 20

-- 7 of 20 --

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may
cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott
undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or
developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika LeBean 224-399-5082
Ryan Aliff, 224-667-2299
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1 In the fourth quarter of 2023, total worldwide sales were $10.241 billion and COVID-19 testing-related sales were $288
million. In the fourth quarter of 2022, total worldwide sales were $10.091 billion and COVID-19 testing-related sales
were $1.069 billion.
2 Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-
related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact
of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly
impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has
determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability
of demand for Covid-19 tests.
3 t:slimX2TM is a trademark of Tandem Diabetes Care, Inc.
4 Diagnostic sales and COVID-19 testing-related sales in 2023 and 2022 are summarized below:
Sales 4Q23 COVID Tests Sales 4Q23
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 1,020 1,514 2,534 224 64 288
Core Laboratory 326 1,044 1,370 1 3 4
Molecular 44 109 153 5 2 7
Rapid Diagnostics 543 319 862 218 59 277
Sales 4Q22 COVID Tests Sales 4Q22
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 1,667 1,610 3,277 776 293 1,069
Core Laboratory 301 963 1,264 3 7 10
Molecular 62 118 180 17 20 37
Rapid Diagnostics 1,216 486 1,702 756 266 1,022
Sales 12M23 COVID Tests Sales 12M23
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 4,329 5,659 9,988 1,255 331 1,586
Core Laboratory 1,243 3,916 5,159 7 13 20
Molecular 172 402 574 24 19 43
Rapid Diagnostics 2,518 1,172 3,690 1,224 299 1,523
Sales 12M22 COVID Tests Sales 12M22
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 8,531 7,938 16,469 5,498 2,870 8,368
Core Laboratory 1,137 3,751 4,888 16 46 62
Molecular 370 625 995 190 221 411
Rapid Diagnostics 6,652 3,409 10,061 5,292 2,603 7,895
-- more --
Page 8 of 20

-- 8 of 20 --

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Fourth Quarter Ended December 31, 2023 and 2022
(in millions, except per share data)
(unaudited)
4Q23 4Q22 % Change
Net Sales $10,241 $10,091 1.5
Cost of products sold, excluding amortization expense 4,556 4,593 (0.8)
Amortization of intangible assets 481 496 (3.1)
Research and development 700 725 (3.6)
Selling, general, and administrative 2,724 2,973 (8.3)
Total Operating Cost and Expenses 8,461 8,787 (3.7)
Operating Earnings 1,780 1,304 36.5
Interest expense, net 70 66 5.9
Net foreign exchange (gain) loss 24 (14) n/m
Other (income) expense, net (109) (68) 60.9
Earnings before taxes 1,795 1,320 36.0
Taxes on earnings 201 287 (29.6)
Net Earnings $1,594 $1,033 54.2
Net Earnings excluding Specified Items, as described below $2,094 $1,811 15.6 1)
Diluted Earnings per Common Share $0.91 $0.59 54.2
Diluted Earnings per Common Share,
excluding Specified Items, as described below $1.19 $1.03 15.5 1)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options 1,748 1,754
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 9 of 20

-- 9 of 20 --

1) 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-
tax charges of $500 million, or $0.28 per share, for intangible amortization, charges related to restructuring
and cost reduction initiatives, expenses associated with acquisitions and other net expenses.
2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-
tax charges of $778 million, or $0.44 per share, for intangible amortization, charges related to restructuring
and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
-- more --
Page 10 of 20

-- 10 of 20 --

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Twelve Months Ended December 31, 2023 and 2022
(in millions, except per share data)
(unaudited)
12M23 12M22 % Change
Net Sales $40,109 $43,653 (8.1)
Cost of products sold, excluding amortization expense 17,975 19,142 (6.1)
Amortization of intangible assets 1,966 2,013 (2.3)
Research and development 2,741 2,888 (5.1)
Selling, general, and administrative 10,949 11,248 (2.7)
Total Operating Cost and Expenses 33,631 35,291 (4.7)
Operating Earnings 6,478 8,362 (22.5)
Interest expense, net 252 375 (33.0)
Net foreign exchange (gain) loss 41 2 n/m
Other (income) expense, net (479) (321) 49.3
Earnings before taxes 6,664 8,306 (19.8)
Taxes on earnings 941 1,373 (31.4) 1)
Net Earnings $5,723 $6,933 (17.5)
Net Earnings excluding Specified Items, as described below $7,802 $9,466 (17.6) 2)
Diluted Earnings per Common Share $3.26 $3.91 (16.6)
Diluted Earnings per Common Share,
excluding Specified Items, as described below $4.44 $5.34 (16.9) 2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options 1,749 1,764
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 11 of 20

-- 11 of 20 --

1) Taxes on Earnings includes the recognition of approximately $22 million and $43 million of excess tax
benefits associated with share-based compensation in 2023 and 2022, respectively.
2) 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-
tax charges of $2.079 billion, or $1.18 per share, for intangible amortization, charges related to restructuring
and cost reduction initiatives, expenses associated with acquisitions and other net expenses.
2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-
tax charges of $2.533 billion, or $1.43 per share, for intangible amortization, charges related to a voluntary
recall and restructuring actions, the impairment of R&D intangible assets, acquisition-related costs and
other net expenses.
-- more --
Page 12 of 20

-- 12 of 20 --

Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Fourth Quarter Ended December 31, 2023 and 2022
(in millions, except per share data)
(unaudited)
4Q23
As
Reported
(GAAP) Specified
Items As
Adjusted
Intangible Amortization $ 481 $ (481) $ —
Gross Margin 5,204 518 5,722
R&D 700 (78) 622
SG&A 2,724 (35) 2,689
Other (income) expense, net (109) (9) (118)
Earnings before taxes 1,795 640 2,435
Taxes on Earnings 201 140 341
Net Earnings 1,594 500 2,094
Diluted Earnings per Share $ 0.91 $ 0.28 $ 1.19
Specified items reflect intangible amortization expense of $481 million and other net expenses of $159 million associated
with restructuring actions, costs associated with acquisitions and other net expenses. See page 17 for additional details
regarding specified items.
4Q22
As
Reported
(GAAP) Specified
Items As
Adjusted
Intangible Amortization $ 496 $ (496) $ —
Gross Margin 5,002 612 5,614
R&D 725 (71) 654
SG&A 2,973 (144) 2,829
Other (income) expense, net (68) (24) (92)
Earnings before taxes 1,320 851 2,171
Taxes on Earnings 287 73 360
Net Earnings 1,033 778 1,811
Diluted Earnings per Share $ 0.59 $ 0.44 $ 1.03
Specified items reflect intangible amortization expense of $496 million and other net expenses of $355 million associated
with restructuring actions, costs associated with acquisitions and other expenses. See page 18 for additional details regarding
specified items.
-- more --
Page 13 of 20

-- 13 of 20 --

Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Twelve Months Ended December 31, 2023 and 2022
(in millions, except per share data)
(unaudited)
12M23
As
Reported
(GAAP) Specified
Items As
Adjusted
Intangible Amortization $ 1,966 $ (1,966) $ —
Gross Margin 20,168 2,109 22,277
R&D 2,741 (222) 2,519
SG&A 10,949 (102) 10,847
Other (income) expense, net (479) 25 (454)
Earnings before taxes 6,664 2,408 9,072
Taxes on Earnings 941 329 1,270
Net Earnings 5,723 2,079 7,802
Diluted Earnings per Share $ 3.26 $ 1.18 $ 4.44
Specified items reflect intangible amortization expense of $1.966 billion and other net expenses of $442 million associated
with restructuring actions, costs associated with acquisitions and other expenses. See page 19 for additional details regarding
specified items.
12M22
As
Reported
(GAAP) Specified
Items As
Adjusted
Intangible Amortization $ 2,013 $ (2,013) $ —
Gross Margin 22,498 2,351 24,849
R&D 2,888 (282) 2,606
SG&A 11,248 (236) 11,012
Other (income) expense, net (321) (55) (376)
Earnings before taxes 8,306 2,924 11,230
Taxes on Earnings 1,373 391 1,764
Net Earnings 6,933 2,533 9,466
Diluted Earnings per Share $ 3.91 $ 1.43 $ 5.34
Specified items reflect intangible amortization expense of $2.013 billion and other net expenses of $911 million that includes
charges for the impairment of R&D intangible assets, costs associated with a product recall and restructuring actions,
acquisition-related costs, and other net expenses. See page 20 for additional details regarding specified items.
-- more --
Page 14 of 20

-- 14 of 20 --

A reconciliation of the fourth-quarter tax rates for 2023 and 2022 is shown below:
4Q23
($ in millions) Pre-Tax
Income Taxes on
Earnings Tax
Rate
As reported (GAAP) $ 1,795 $ 201 11.2%
Specified items 640 140
Excluding specified items $ 2,435 $ 341 14.0%
4Q22
($ in millions) Pre-Tax
Income Taxes on
Earnings Tax
Rate
As reported (GAAP) $ 1,320 $ 287 21.7%
Specified items 851 73
Excluding specified items $ 2,171 $ 360 16.5%
A reconciliation of the year-to-date tax rates for 2023 and 2022 is shown below:
12M23
($ in millions) Pre-Tax
Income Taxes on
Earnings Tax
Rate
As reported (GAAP) $ 6,664 $ 941 14.1% 1)
Specified items 2,408 329
Excluding specified items $ 9,072 $ 1,270 14.0%
12M22
($ in millions) Pre-Tax
Income Taxes on
Earnings Tax
Rate
As reported (GAAP) $ 8,306 $ 1,373 16.5% 2)
Specified items 2,924 391
Excluding specified items $ 11,230 $ 1,764 15.7%
1) 2023 Taxes on Earnings includes the recognition of approximately $22 million in excess tax benefits
associated with share-based compensation.
2) 2022 Taxes on Earnings includes the recognition of approximately $43 million in excess tax benefits
associated with share-based compensation.
-- more --
Page 15 of 20

-- 15 of 20 --

Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Fourth Quarter and Twelve Months Ended December 31, 2023 and 2022
($ in millions)
(unaudited)
4Q23 4Q22 % Change vs. 4Q22
Non-GAAP
Abbott
Reported
Impact
of CSI
acquisition
(a)
Impact from
business exit
(b) Adjusted
Revenue Abbott
Reported
Impact from
business exit
(b) Adjusted
Revenue Reported Adjusted Organic
Total Company 10,241 (40) (7) 10,194 10,091 (23) 10,068 1.5 1.3 2.1
U.S. 3,949 (38) — 3,911 4,219 — 4,219 (6.4) (7.3) (7.3)
Intl 6,292 (2) (7) 6,283 5,872 (23) 5,849 7.2 7.4 8.8
Total Nutrition 2,038 — (7) 2,031 1,817 (23) 1,794 12.2 13.2 13.9
U.S. 860 — — 860 795 — 795 8.2 8.2 8.2
Intl 1,178 — (7) 1,171 1,022 (23) 999 15.3 17.2 18.5
Pediatric Nutrition 985 — (7) 978 882 (23) 859 11.8 14.0 14.5
U.S. 505 — — 505 454 — 454 11.4 11.4 11.4
Intl 480 — (7) 473 428 (23) 405 12.3 16.9 17.9
Total Medical Devices 4,443 (40) — 4,403 3,778 — 3,778 17.5 16.4 15.4
U.S. 2,065 (38) — 2,027 1,754 — 1,754 17.6 15.5 15.5
Intl 2,378 (2) — 2,376 2,024 — 2,024 17.5 17.4 15.4
Vascular 677 (40) — 637 605 — 605 12.0 5.6 4.5
U.S. 245 (38) — 207 214 — 214 14.8 (2.5) (2.5)
Intl 432 (2) — 430 391 — 391 10.4 9.9 8.3
12M23 12M22 % Change vs. 12M22
Non-GAAP
Abbott
Reported
Impact
of CSI
acquisition
(a)
Impact from
business exit
(b) Adjusted
Revenue Abbott
Reported
Impact from
business exit
(b) Adjusted
Revenue Reported Adjusted Organic
Total Company 40,109 (130) (48) 39,931 43,653 (135) 43,518 (8.1) (8.2) (6.2)
U.S. 15,452 (123) — 15,329 18,142 — 18,142 (14.8) (15.5) (15.5)
Intl 24,657 (7) (48) 24,602 25,511 (135) 25,376 (3.3) (3.0) 0.5
Total Nutrition 8,154 — (48) 8,106 7,459 (135) 7,324 9.3 10.7 13.0
U.S. 3,413 — — 3,413 2,919 — 2,919 16.9 16.9 16.9
Intl 4,741 — (48) 4,693 4,540 (135) 4,405 4.4 6.6 10.4
Pediatric Nutrition 3,934 — (48) 3,886 3,481 (135) 3,346 13.0 16.1 17.9
U.S. 1,977 — — 1,977 1,562 — 1,562 26.6 26.6 26.6
Intl 1,957 — (48) 1,909 1,919 (135) 1,784 2.0 7.1 10.3
Total Medical Devices 16,887 (130) — 16,757 14,802 — 14,802 14.1 13.2 14.2
U.S. 7,696 (123) — 7,573 6,681 — 6,681 15.2 13.3 13.3
Intl 9,191 (7) — 9,184 8,121 — 8,121 13.2 13.1 14.9
Vascular 2,681 (130) — 2,551 2,483 — 2,483 8.0 2.7 4.0
U.S. 978 (123) — 855 864 — 864 13.2 (1.0) (1.0)
Intl 1,703 (7) — 1,696 1,619 — 1,619 5.2 4.7 6.7
(a) Reflects the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023.
(b) Reflects the impact of exiting the pediatric nutrition business in China. This action was initiated in December 2022.
-- more --
Page 16 of 20

-- 16 of 20 --

Abbott Laboratories and Subsidiaries
Details of Specified Items
Fourth Quarter Ended December 31, 2023
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b) Intangible
Amortization Other (c) Total
Specifieds
Gross Margin $ 1 $ 29 $ 481 $ 7 $ 518
R&D (6) (4) — (68) (78)
SG&A (15) (5) — (15) (35)
Other (income) expense, net (6) — — (3) (9)
Earnings before taxes $ 28 $ 38 $ 481 $ 93 640
Taxes on Earnings (d) 140
Net Earnings $ 500
Diluted Earnings per Share $ 0.28
The table above provides additional details regarding the specified items described on page 13.
a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating
acquired businesses, as well as legal and other costs related to business acquisitions.
b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with
specific restructuring plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro
Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible
asset impairments.
d) Reflects the net tax benefit associated with the specified items.
-- more --
Page 17 of 20

-- 17 of 20 --

Abbott Laboratories and Subsidiaries
Details of Specified Items
Fourth Quarter Ended December 31, 2022
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b) Intangible
Amortization Other (c) Total
Specifieds
Gross Margin $ 23 $ 87 $ 496 $ 6 $ 612
R&D (6) (34) — (31) (71)
SG&A (7) (135) — (2) (144)
Other (income) expense, net 3 — — (27) (24)
Earnings before taxes $ 33 $ 256 $ 496 $ 66 851
Taxes on Earnings (d) 73
Net Earnings $ 778
Diluted Earnings per Share $ 0.44
The table above provides additional details regarding the specified items described on page 13.
a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the
acquired businesses and include expenditures for the integration of systems, processes and business activities.
b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with
specific restructuring plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro
Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products as well as the impairment of an
equity investment.
d) Reflects the net tax benefit associated with the specified items.
-- more --
Page 18 of 20

-- 18 of 20 --

Abbott Laboratories and Subsidiaries
Details of Specified Items
Twelve Months Ended December 31, 2023
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b) Intangible
Amortization Other (c) Total
Specifieds
Gross Margin $ 16 $ 80 $ 1,966 $ 47 $ 2,109
R&D (19) (9) — (194) (222)
SG&A (58) (33) — (11) (102)
Other (income) expense, net 40 — — (15) 25
Earnings before taxes $ 53 $ 122 $ 1,966 $ 267 2,408
Taxes on Earnings (d) 329
Net Earnings $ 2,079
Diluted Earnings per Share $ 1.18
The table above provides additional details regarding the specified items described on page 14.
a) Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which
represent incremental costs directly related to integrating acquired businesses.
b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with
specific restructuring plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges
for intangible asset impairments.
d) Reflects the net tax benefit associated with the specified items.
-- more --
Page 19 of 20

-- 19 of 20 --

Abbott Laboratories and Subsidiaries
Details of Specified Items
Twelve Months Ended December 31, 2022
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b) Intangible
Amortization Other (c) Total
Specifieds
Gross Margin $ 79 $ 86 $ 2,013 $ 173 $ 2,351
R&D (16) (38) — (228) (282)
SG&A (38) (140) — (58) (236)
Other (income) expense, net (12) — — (43) (55)
Earnings before taxes $ 145 $ 264 $ 2,013 $ 502 2,924
Taxes on Earnings (d) 391
Net Earnings $ 2,533
Diluted Earnings per Share $ 1.43
The table above provides additional details regarding the specified items described on page 14.
a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the
acquired businesses and include expenditures for the integration of systems, processes and business activities.
b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with
specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the
charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19
diagnostic tests.
c) Other primarily relates to the net costs related to a voluntary recall within the Nutrition segment, charges associated with the
impairments of R&D intangible assets and an equity investment acquired in a business combination, incremental costs to
comply with the European Union's MDR and IVDR Regulations for previously approved products and costs related to certain
litigation.
d) Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation
and net tax expense as a result of the resolution of various tax positions related to prior years.
###
Page 20 of 20

-- 20 of 20 --